BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 19247083)

  • 1. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
    Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
    J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.
    Sasaki H; Endo K; Okuda K; Kawano O; Kitahara N; Tanaka H; Matsumura A; Iuchi K; Takada M; Kawahara M; Kawaguchi T; Yukiue H; Yokoyama T; Yano M; Fujii Y
    J Cancer Res Clin Oncol; 2008 May; 134(5):569-77. PubMed ID: 17932690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
    Daniele L; Macrì L; Schena M; Dongiovanni D; Bonello L; Armando E; Ciuffreda L; Bertetto O; Bussolati G; Sapino A
    Mol Cancer Ther; 2007 Apr; 6(4):1223-9. PubMed ID: 17406029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
    J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.
    Sone T; Kasahara K; Kimura H; Nishio K; Mizuguchi M; Nakatsumi Y; Shibata K; Waseda Y; Fujimura M; Nakao S
    Cancer; 2007 May; 109(9):1836-44. PubMed ID: 17387741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
    Hirsch FR; Varella-Garcia M; Cappuzzo F; McCoy J; Bemis L; Xavier AC; Dziadziuszko R; Gumerlock P; Chansky K; West H; Gazdar AF; Crino L; Gandara DR; Franklin WA; Bunn PA
    Ann Oncol; 2007 Apr; 18(4):752-60. PubMed ID: 17317677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
    Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
    Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
    Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
    Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
    Cappuzzo F; Toschi L; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Cancellieri A; Magrini E; Bemis L; Franklin WA; Crino L; Bunn PA; Hirsch FR; Varella-Garcia M
    Br J Cancer; 2005 Dec; 93(12):1334-40. PubMed ID: 16288303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
    Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
    J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.
    Soh J; Toyooka S; Ichihara S; Fujiwara Y; Hotta K; Suehisa H; Kobayashi N; Ichimura K; Aoe K; Aoe M; Kiura K; Date H
    Int J Cancer; 2007 Sep; 121(5):1162-7. PubMed ID: 17487844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
    Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
    J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
    D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
    J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Zucali PA; Ruiz MG; Giovannetti E; Destro A; Varella-Garcia M; Floor K; Ceresoli GL; Rodriguez JA; Garassino I; Comoglio P; Roncalli M; Santoro A; Giaccone G
    Ann Oncol; 2008 Sep; 19(9):1605-12. PubMed ID: 18467317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
    Gandhi J; Zhang J; Xie Y; Soh J; Shigematsu H; Zhang W; Yamamoto H; Peyton M; Girard L; Lockwood WW; Lam WL; Varella-Garcia M; Minna JD; Gazdar AF
    PLoS One; 2009; 4(2):e4576. PubMed ID: 19238210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.
    Cappuzzo F; Marchetti A; Skokan M; Rossi E; Gajapathy S; Felicioni L; Del Grammastro M; Sciarrotta MG; Buttitta F; Incarbone M; Toschi L; Finocchiaro G; Destro A; Terracciano L; Roncalli M; Alloisio M; Santoro A; Varella-Garcia M
    J Clin Oncol; 2009 Apr; 27(10):1667-74. PubMed ID: 19255323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.
    Sutiman N; Tan SW; Tan EH; Lim WT; Kanesvaran R; Ng QS; Jain A; Ang MK; Tan WL; Toh CK; Chowbay B
    J Thorac Oncol; 2017 Mar; 12(3):529-538. PubMed ID: 27908825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
    Ko R; Kenmotsu H; Hisamatsu Y; Akamatsu H; Omori S; Nakashima K; Oyakawa T; Wakuda K; Shukuya T; Ono A; Imai H; Taira T; Naito T; Murakami H; Mori K; Endo M; Ohde Y; Takahashi K; Takahashi T
    Int J Clin Oncol; 2015 Aug; 20(4):668-73. PubMed ID: 25343946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.